|
Factors affecting time to active therapy (AT) among patients (pts) with myelodysplastic syndromes (MDS) in a US electronic medical records (EMR) database. |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Celgene |
Travel, Accommodations, Expenses - Celgene |
| |
|
|
Stock and Other Ownership Interests - Celgene |
| |
|
Consulting or Advisory Role - Celgene |
| |
|
Stock and Other Ownership Interests - ARIAD; Synta |
Consulting or Advisory Role - Amgen; Celgene; Genoptix; Incyte; Novartis |
| |
|
Consulting or Advisory Role - Celgene; Incyte |
| |
|
|
Stock and Other Ownership Interests - Celgene |
| |
|
|
Stock and Other Ownership Interests - Celgene |